TiGenix NV (NYSE Euronext: TIG) is a leading European cell therapy company with an advanced clinical stage pipeline of adult stem cell programmes, and a commercialised product.

The stem cell programmes are based on a validated platform of allogeneic expanded adipose-derived stem cells (eASCs) targeting autoimmune and inflammatory diseases. Built on solid pre-clinical and CMC packages, they are being developed in close consultation with the European Medicines Agency.  CX601 is in Phase III to treat complex perianal fistulas in patients with Crohn’s disease. Cx611 has successfully concluded a Phase IIa trial in rheumatoid arthritis, and is now in development for early rheumatoid arthritis and for severe sepsis.

The company’s commercialised product, ChondroCelect®, for cartilage repair in the knee, was the first approved cell-based product in Europe, and is marketed and distributed by Swedish Orphan Biovitrum AB (‘Sobi’, NASDAQ OMX Stockholm: SOBI) and Finnish Red Cross Blood Service (FRCBS). TiGenix is based in Leuven, Belgium, and has operations in Madrid , Spain.



Pipeline Update


Latest News

27 February 2015 - TiGenix NV successfully places EUR 25 million convertible bonds (EN - NL - FR - ES)

26 February 2015 - TiGenix launches an offering of EUR 25 million convertible bonds (EN - NL - FR - ES)

26 February 2015 - Special report of the Board of Directors (EN - NL)

23 February 2015 - TiGenix’s Phase III trial design for Cx601 endorsed by President-Elect of ECCO (EN - NL - FR)

12 February 2015 - TiGenix and Lonza sign agreement for the manufacture of stem cell-based treatment of complex perianal fistulas in Crohn’s disease (EN - NL - FR)


Company presentation slide deck

2015 - Corporate Presentation

Management presentations

TiGenix - Company Presentation